Mastocytosis and Anaphylaxis

Immunology and Allergy Clinics of North America

Volumn 37, Issue 1, 2017, Pages 153-164

  Schuch, Anna ^a   Brockow, Knut ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anaphylaxis; Drug induced anaphylaxis; Hymenoptera venom anaphylaxis; Mast cell activation syndrome; Mastocytosis; Risk factors; Triggers

Indexed keywords

BETA LACTAM; CLADRIBINE; CONTRAST MEDIUM; CORTICOSTEROID; CROMOGLYCATE DISODIUM; EPINEPHRINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; OPIATE; SALBUTAMOL; VENOM; ALLERGEN; ARTHROPOD VENOM;

ALLERGY; ANAPHYLAXIS; ANESTHESIA; ATOPY; BRONCHOSPASM; CLINICAL FEATURE; EMERGENCY CARE; FOOD ANAPHYLAXIS; HUMAN; HYMENOPTERA VENOM ANAPHYLAXIS; IDIOPATHIC DISEASE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MAST CELL; MAST CELL ACTIVATION SYNDROME; MASTOCYTOSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; ADULT; ANIMAL; CHILD; DRUG HYPERSENSITIVITY; HYMENOPTERA; IMMUNOLOGY; INSECT BITE;

ADULT; ALLERGENS; ANAPHYLAXIS; ANIMALS; ARTHROPOD VENOMS; CHILD; DRUG HYPERSENSITIVITY; HUMANS; HYMENOPTERA; INSECT BITES AND STINGS; MAST CELLS; MASTOCYTOSIS; RISK FACTORS;

EID: 84996928503     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2016.08.017     Document Type: Review

References (68)

1. 1 Theoharides, T.C., Valent, P., Akin, C., Mast cells, mastocytosis, and related disorders. N Engl J Med 373:2 (2015), 163–172.
2. 2 Escribano, L., Orfao, A., Anaphylaxis in mastocytosis. Castells, M.C., (eds.) Anaphylaxis and hypersensitivity reactions, 2011, Springer Science+Business Media, LLC, New York, 257–270.
3. 3 Nagata, H., Worobec, A.S., Oh, C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92:23 (1995), 10560–10564.
4. 4 Hägglund, H., Sander, B., Ahmadi, A., et al. Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis. Med Oncol, 31(8), 2014, 123.
5. 5 Valent, P., Horny, H.P., Escribano, L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 (2001), 603–625.
6. 6 Brockow, K., Ring, J., Update on diagnosis and treatment of mastocytosis. Curr Allergy Asthma Rep 11 (2011), 292–299.
7. 7 Escribano, L., Alvarez-Twose, I., Sanchez-Munoz, L., et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124 (2009), 514–521.
8. 8 Alvarez-Twose, I., Zanotti, R., Gonzalez-de-Olano, D., et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 133:2 (2014), 520–528.
9. 9 Zanotti, R., Bonadonna, P., Bonifacio, M., et al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica 96:3 (2011), 482–484.
10. 10 Valent, P., Arock, M., Akin, C., et al. The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood 116 (2010), 850–851.
11. 11 Simons, F.E., Ardusso, L.R., Bilò, M.B., et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 127:3 (2011), 587–593.
12. 12 Sampson, H.A., Munoz-Furlong, A., Campbell, R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117:2 (2006), 391–397.
13. 13 Sonneck, K., Florian, S., Mullauer, L., et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 142 (2007), 158–164.
14. 14 Akin, C., Scott, L.M., Kocabas, C.N., et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood 110 (2007), 2332–2333.
15. 15 Golkar, L., Bernhard, J.D., Mastocytosis. Lancet 349 (1997), 1379–1385.
16. 16 van Doormaal, J.J., Arends, S., Brunekreeft, K.L., et al. Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol 131 (2013), 1429–1431.
17. 17 Cohen, S.S., Skovbo, S., Vestergaard, H., et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 166:4 (2014), 521–528.
18. 18 Brockow, K., Akin, C., Huber, M., et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels and bone marrow pathology. J Am Acad Dermatol 48 (2003), 508–516.
19. 19 González-de-Olano, D., de la Hoz, B., Nunez-Lopez, R., et al. Prevalence of allergy and anaphylactic symptoms in 210 adults and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 37 (2007), 1547–1555.
20. 20 Wood, R.A., Camargo, C.A. Jr., Lieberman, P., et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol 133:2 (2014), 461–467.
21. 21 Panesar, S.S., Javad, S., de Silva, D., et al. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 68:11 (2013), 1353–1361.
22. 22 Brockow, K., Jofer, C., Behrendt, H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 63 (2008), 226–232.
23. 23 Gülen, T., Hägglund, H., Dahlén, B., et al. High prevalence of anaphylaxis in patients with systemic mastocytosis: a single-centre experience. Clin Exp Allergy 44:1 (2014), 121–129.
24. 24 Barnes, M., Van, L., DeLong, L., et al. Severity of cutaneous findings predict the presence of systemic symptoms in pediatric maculopapular cutaneous mastocytosis. Pediatr Dermatol 31:3 (2014), 271–275.
25. 25 Matito, A., Carter, M., Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?. Curr Allergy Asthma Rep, 15(5), 2015, 22.
26. 26 Alvarez-Twose, I., Vano-Galvan, S., Sanchez-Munoz, L., et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy 67 (2012), 813–821.
27. 27 Brockow, K., Ring, J., Alvarez-Twose, I., et al. Extensive blistering is a predictor for severe complications in children with mastocytosis. Allergy 67:10 (2012), 1323–1324.
28. 28 Górska, A., Niedoszytko, M., Lange, M., et al. Risk factors for anaphylaxis in patients with mastocytosis. Pol Arch Med Wewn 125:1–2 (2015), 46–53.
29. 29 Alvarez-Twose, I., González de Olano, D., Sánchez-Munos, L., et al. Clinical, biological and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 125:6 (2010), 1269–1278.
30. 30 van Anrooij, B., van der Veer, E., de Monchy, J.G., et al. Higher mast cell load decreases risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol 132 (2013), 125–130.
31. 31 Broesby-Olsen, S., Kristensen, T., Vestergaard, H., et al. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol 132:3 (2013), 723–728.
32. 32 Grabbe, J., Welker, P., Dippel, E., et al. Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch Dermatol Res 287:1 (1994), 78–84.
33. 33 Koterba, A., Akin, C., Differences in the clinical presentation of anaphylaxis in patients with indolent systemic mastocytosis versus idiopathic anaphylaxis [abstract]. J Allergy Clin Immunol, 121, 2008, S68.
34. 34 Bonadonna, P., Zanotti, R., Pagani, M., et al. How much specific is the association between Hymenoptera venom allergy and mastocytosis?. Allergy 64:9 (2009), 1379–1382.
35. 35 Worobec, A.S., Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 14 (2000), 659–687.
36. 36 Bonadonna, P., Perbellini, O., Passalacqua, G., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 123 (2009), 680–686.
37. 37 Ludolph-Hauser, D., Rueff, F., Fries, C., et al. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 357 (2001), 361–362.
38. 38 Rueff, F., Przybilla, B., Biló, M.B., et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase. A study of the European Academy of Allergology and clinical immunology interest group on insect venom hypersensitivity. J Allergy Clin Immunol 124 (2009), 1047–1054.
39. 39 Potier, A., Lavigne, C., Chappard, D., et al. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin Exp Allergy 39 (2009), 717–725.
40. 40 Michel, J., Brockow, K., Darsow, U., et al. Added sensitivity of component-resolved diagnosis in Hymenoptera venom-allergic patients with elevated serum tryptase and/or mastocytosis. Allergy 71:5 (2016), 651–660.
41. 41 González-de-Olano, D., Alvarez-Twose, I., Morgado, J.M., et al. Evaluation of basophil activation in mastocytosis with Hymenoptera venom anaphylaxis. Cytometry B Clin Cytom 80:3 (2011), 167–175.
42. 42 Roenneberg, S., Boehner, A., Brockow, K., et al. Alpha-Gal: a new clue for anaphylaxis in mastocytosis. J Allergy Clin Immunol Pract 4:3 (2016), 531–532.
43. 43 Prieto-García, A., Álvarez-Perea, A., Matito, A., et al. Systemic mastocytosis presenting as IgE-mediated food-induced anaphylaxis: a report of two cases. J Allergy Clin Immunol Pract 3:3 (2015), 456–458.
44. 44 Brockow, K., Bonadonna, P., Drug allergy in mast cell disease. Curr Opin Allergy Clin Immunol 12 (2012), 354–360.
45. 45 Vaughan, S.T.A., Jones, G.N., Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia 53 (1993), 804–807.
46. 46 Tirel, O., Chaumont, A., Ecoffey, C., Circulatory arrest in the course of anaesthesia for a child with mastocytosis. Ann Fr Anesth Reanim 20 (2001), 874–875 [in French].
47. 47 Matito, A., Morgado, J.M., Sánchez-López, P., et al. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish network on mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol 167:1 (2015), 47–56.
48. 48 Yocum, M.W., Butterfield, J.H., Gharib, H., Increased plasma calcitonin levels in systemic mast cell disease. Mayo Clin Proc 69:10 (1994), 987–990.
49. 49 Seitz, C.S., Brockow, K., Hain, J., et al. Non-steroidal anti-inflammatory drug hypersensitivity: association with elevated basal serum tryptase?. Allergy Asthma Clin Immunol, 10(1), 2014, 19.
50. 50 Valent, P., Akin, C., Arock, M., et al. Definition, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157 (2012), 215–225.
51. 51 Haeberli, G., Bronnimann, M., Hunziker, T., et al. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 33 (2003), 1216–1220.
52. 52 Irani, A.M., Akl, E.G., Management and prevention of anaphylaxis. F1000Res, 22, 2015, 4.
53. 53 Simons, F.E., Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol 124:4 (2009), 625–636.
54. 54 Przybilla, B., Rueff, F., Fuchs, T., et al. Insektengiftallergie. Allergo J 13 (2004), 186–190.
55. 55 Brockow, K., Schallmayer, S., Beyer, K., et al. Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis. Allergy 70:2 (2015), 227–235.
56. 56 Soar, J., Pumphrey, R., Cant, A., et al. Emergency treatment of anaphylactic reactions: guidelines for healthcare providers. Resuscitation 77:2 (2008), 157–169.
57. 57 Niedoszytko, M., de Monchy, J., van Doormaal, J.J., et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 64 (2009), 1237–1245.
58. 58 Rueff, F., Placzek, M., Przybilla, B., Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 6 (2006), 284–288.
59. 59 Gonzalez de Olano, D., Varez-Twose, I., Esteban-Lopes, M.I., et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 121 (2008), 519–526.
60. 60 Fricker, M., Helbling, A., Schwartz, L., et al. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 100 (1997), 11–15.
61. 61 Rueff, F., Wenderoth, A., Przybilla, B., Patients still reacting to a sting challenge while receiving Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108 (2001), 1027–1032.
62. 62 Elberink, J.N.G.O., de Monchy, J.G.R., Kors, J.W., et al. Fatal anaphylaxis after yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 99 (1997), 153–154.
63. 63 Reimers, A., Müller, U., Fatal outcome of a vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. Allergy Clin Immunol Int J WAO Org 17:1 (2005), 69–70.
64. 64 Carter, M.C., Uzzaman, A., Scott, L.M., et al. Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg 197:2 (2008), 422–427.
65. 65 Sokol, K.C., Ghazi, A., Kelly, B.C., et al. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract 2:3 (2014), 266–270.
66. 66 Wimazal, F., Geissler, P., Shnawa, P., et al. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol 157:4 (2012), 399–405.
67. 67 Gotlib, J., Kluin-Nelemans, H.C., George, T.I., et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374:26 (2016), 2530–2541.
68. 68 Arock, M., Akin, C., Hermine, O., et al. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. Eur J Haematol 94:6 (2015), 474–490.